MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 564337 | Name: Aldoxorubicin free base

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Aldoxorubicin, also known as INNO-206 and Doxorubicin-EMCH, is a prodrug of the anthracycline antibiotic doxorubicin. Aldoxorubicin binds selectively to the cysteine-34 position of albumin via its maleimide moiety, inhibiting DNA synthesis and inducing apoptosis.

Chemical Structure

Aldoxorubicin free base
Aldoxorubicin free base
CAS#1361644-26-9 (free base)

Theoretical Analysis

MedKoo Cat#: 564337

Name: Aldoxorubicin free base

CAS#: 1361644-26-9 (free base)

Chemical Formula: C37H42N4O13

Exact Mass: 750.2748

Molecular Weight: 750.76

Elemental Analysis: C, 59.19; H, 5.64; N, 7.46; O, 27.70

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
1361644-26-9 (free base) 480998-12-7 (HCl) 151038-96-9 (free base)
Synonym
INNO206; INNO 206; INNO-206; Doxorubicin-EMCH; Aldoxorubicin free base
IUPAC/Chemical Name
N-[(E)-[1-[(2S,4S)-4-[(2R,4S,5S,6S)-4-Amino-5-hydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]-2-hydroxyethylidene]amino]-6-(2,5-dioxopyrrol-1-yl)hexanamide
InChi Key
OBMJQRLIQQTJLR-USGQOSEYSA-N
InChi Code
InChI=1S/C37H42N4O13/c1-17-32(46)20(38)13-27(53-17)54-22-15-37(51,23(16-42)39-40-24(43)9-4-3-5-12-41-25(44)10-11-26(41)45)14-19-29(22)36(50)31-30(34(19)48)33(47)18-7-6-8-21(52-2)28(18)35(31)49/h6-8,10-11,17,20,22,27,32,42,46,48,50-51H,3-5,9,12-16,38H2,1-2H3,(H,40,43)/b39-23+/t17-,20-,22-,27-,32+,37-/m0/s1
SMILES Code
O=C(N/N=C([C@@]1(O)C[C@H](O[C@@H]2O[C@@H](C)[C@@H](O)[C@@H](N)C2)C3=C(O)C4=C(C(C5=CC=CC(OC)=C5C4=O)=O)C(O)=C3C1)\CO)CCCCCN6C(C=CC6=O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 750.76 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Seetharam M, Kolla KR, Ganjoo KN. Aldoxorubicin therapy for the treatment of patients with advanced soft tissue sarcoma. Future Oncol. 2018 Oct;14(23):2323-2333. doi: 10.2217/fon-2018-0047. Epub 2018 Jun 5. PubMed PMID: 29869517. 2: Gong J, Yan J, Forscher C, Hendifar A. Aldoxorubicin: a tumor-targeted doxorubicin conjugate for relapsed or refractory soft tissue sarcomas. Drug Des Devel Ther. 2018 Apr 6;12:777-786. doi: 10.2147/DDDT.S140638. eCollection 2018. Review. PubMed PMID: 29670334; PubMed Central PMCID: PMC5896668. 3: Sachdev E, Sachdev D, Mita M. Aldoxorubicin for the treatment of soft tissue sarcoma. Expert Opin Investig Drugs. 2017 Oct;26(10):1175-1179. doi: 10.1080/13543784.2017.1371134. Epub 2017 Aug 28. Review. PubMed PMID: 28846045. 4: Chugh R, Schuetze SM. Aldoxorubicin in Sarcoma: Teaching an Old Drug New Tricks. JAMA Oncol. 2015 Dec;1(9):1280-1. doi: 10.1001/jamaoncol.2015.3221. PubMed PMID: 26379207. 5: Chawla SP, Papai Z, Mukhametshina G, Sankhala K, Vasylyev L, Fedenko A, Khamly K, Ganjoo K, Nagarkar R, Wieland S, Levitt DJ. First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma: A Phase 2b Randomized Clinical Trial. JAMA Oncol. 2015 Dec;1(9):1272-80. doi: 10.1001/jamaoncol.2015.3101. PubMed PMID: 26378637. 6: Mita MM, Natale RB, Wolin EM, Laabs B, Dinh H, Wieland S, Levitt DJ, Mita AC. Pharmacokinetic study of aldoxorubicin in patients with solid tumors. Invest New Drugs. 2015 Apr;33(2):341-8. doi: 10.1007/s10637-014-0183-5. Epub 2014 Nov 12. PubMed PMID: 25388939; PubMed Central PMCID: PMC4387275. 7: Chawla SP, Chua VS, Hendifar AF, Quon DV, Soman N, Sankhala KK, Wieland DS, Levitt DJ. A phase 1B/2 study of aldoxorubicin in patients with soft tissue sarcoma. Cancer. 2015 Feb 15;121(4):570-9. doi: 10.1002/cncr.29081. Epub 2014 Oct 13. PubMed PMID: 25312684. 8: Marrero L, Wyczechowska D, Musto AE, Wilk A, Vashistha H, Zapata A, Walker C, Velasco-Gonzalez C, Parsons C, Wieland S, Levitt D, Reiss K, Prakash O. Therapeutic efficacy of aldoxorubicin in an intracranial xenograft mouse model of human glioblastoma. Neoplasia. 2014 Oct 23;16(10):874-82. doi: 10.1016/j.neo.2014.08.015. eCollection 2014 Oct. PubMed PMID: 25379024; PubMed Central PMCID: PMC4212249.